Skip to main content

Fiscal Wizard · Single-issue tearsheet

KNSA / Jun 22, 2026 Run #7615

KNSA

Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Composite verdict

B 71.1 / 100
Bullish setup · Trend Following 10 drivers · 3 gates blocking
  • Coppock Curve
  • SuperTrend
  • Rate of Change
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 6th of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: range
Bull 100%Evidence: High · 17 signals0% Bear
Momentum Bullish 95Mean-reversion Neutral 55

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -82%
Asset value $12.26Earnings power value $15.67Price $55.11

Priced above its no-growth earnings power value ($15.67/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

42.3 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Days Sales Outstanding 100
Margin of Safety 0
EPS Growth (YoY) 100
OCF to Net Income 0
Revenue Growth (YoY) 100
Cash Conversion 0

Technicals Bullish

99.9 / 100

Bullish setup leads (Coppock Curve, SuperTrend, Rate of Change); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Coppock Curve 90
SuperTrend 89
Rate of Change 87

Risk Gates

3 blocking 6 caution

3 guards active, 22 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for KNSA.